Immune system activated in schizophrenia

	Tweet

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

The causes of schizophrenia are largely unknown, and this hinders the development of effective treatments. One theory is that infections caught early on in life might increase the risk of developing schizophrenia, but to date any direct evidence of this has not been forthcoming.

Scientists at Karolinska Institutet have now been able to analyse inflammatory substances in the spinal fluid of patients with schizophrenia, instead of, as in previous studies, in the blood. The results show that patients with recent-onset schizophrenia have raised levels of a signal substance called interleukin-1beta, which can be released in the presence of inflammation. In the healthy control patients, this substance was barely measurable. 

"This suggests that the brain’s immune defence system is activated in schizophrenia,” says Professor Göran Engberg, who led the study. “It now remains to be seen whether there is an underlying infection or whether the immune system is triggered by some other means.”

According to the dominant hypothesis, schizophrenia is related to an overactive dopamine system. Previous studies have shown that interleukin-1beta can upset the dopamine system in rats in a similar way to schizophrenia in humans.

“We would have made terrific progress if we were one day able to treat schizophrenia patients with immunotherapy, as it might then be possible to interrupt the course of the disease at an early stage of its development,” says Professor Engberg.

The group is now studying if the inflammatory process is only activated in connection with the development of schizophrenia, or whether chronic patients exhibit the same phenomenon.

Publication
J Söderlund, J Schröder, C Nordin, M Samuelsson, L Walther-Jallow, H Karlsson, S Erhardt, G Engberg
Activation of brain interleukin-1² in schizophrenia

Molecular Psychiatry, vol.14; no. 12; November 2009

Professor Göran Engberg
Department of Physiology and Pharmacology

Work
+46 (0)8 524 867 17
Mobile
+46 (0)70 352 67 17

E-mail:

PhD Johan Söderlund
Department of Physiology and Pharmacology

Mobile
+46 (0)73 655 37 63

E-mail:

RELATED STORIES:
Mice with Defective Memory May Hold Clues to Schizophrenia   Schizophrenia-type illness linked to heart risk   Clozaril useful as second schizophrenia drug   New Candidate Genes for Schizophrenia Identified   Heart Disease a ‘Silent Killer’ in Patients With Severe Mental Illness   Major schizophrenia study finds striking similarities across 37 countries in 6 regions   In schizophrenia, MDs should target pot use: study   Zyprexa Trial in Schizophrenia ‘Prodome’ Yields Only Hints   Glutamate: Too much of a good thing in schizophrenia?   How to treat nicotine dependence in smokers with schizophrenia   The accuracy of the ASEX to identify sexual dysfunction in patients of the schizophrenia spectrum   Sexual dysfunction and schizophrenia: psychiatrists’ attitudes and training needs   Normal role for schizophrenia risk gene identified   Study strongly supports many genetic contributions to schizophrenia, bipolar disorder   Scientists identify gene that may indicate predisposition to schizophrenia

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]